Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 15/20 | 0.57 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3155460 | 0.90 | MAPK1 (0.63) | MAPK1MAPK3ALDH1A1MAPT | |
| SCHEMBL4220089 | 0.81 | MAPK1 (0.51) | MAPK1MAPK3ALDH1A1MAPTMAP2K2 | |
| SCHEMBL2466579 | 0.81 | MAPK1 (0.64) | MAPK1MAPK3ALDH1A1MAPTMAP2K2 | |
| SCHEMBL2471086 | 0.80 | MAPK1 (0.52) | MAPK1MAPK3ALDH1A1MAPTMAP2K2 | |
| SCHEMBL2468669 | 0.79 | MAPK1 (0.91) | MAPK1MAPK3 | |
| SCHEMBL4231255 | 0.79 | MAPK1 (0.52) | MAPK1MAPK3ALDH1A1MAPTMAP2K2 | |
| SCHEMBL4213861 | 0.79 | MAPK1 (0.51) | MAPK1MAPK3ALDH1A1MAPTMAP2K2 | |
| SCHEMBL2471090 | 0.76 | MAPK1 (0.63) | MAPK1MAPK3MAP2K2MAP2K1MAPK6 | |
| SCHEMBL3153368 | 0.76 | MAPK1 (0.55) | MAPK1MAPK3ALDH1A1MAPT | |
| SCHEMBL3155813 | 0.76 | MAPK1 (0.55) | MAPK1MAPK3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| EP-1966151-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | MAPK1 1/4885MAPK3 6/4885ALDH1A1 277/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | MAPK1 1/4885MAPK3 7/4885ALDH1A1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.